Use XRPD for solid-form identification, quantitation, method development, validation, release, and stability support.
For cGMP work, method choice has to follow the quality attribute, sample matrix, method status, documentation need, and regulatory decision. The testing plan should connect method development, validation, method transfer, release testing, CoA support, and documentation requirements rather than treating each instrument run as an isolated activity. For XRPD, this includes alignment with USP <941> general chapter concepts where applicable, and Triclinic has verified cGMP XRPD testing for regulated use.
cGMP XRPD is regulated X-ray powder diffraction testing used to identify and quantify crystalline phases, confirm form, evaluate crystallinity, support release/stability methods, and monitor process-related form control. Where applicable, USP <941> provides the general-chapter framework for XRPD characterization of crystalline and partially crystalline solids.
Use it when polymorph, hydrate, solvate, cocrystal, salt, crystalline impurity, or amorphous/crystalline balance may affect quality, dissolution, stability, or specifications.
XRPD is less sensitive for low-level phases in complex matrices, can be affected by preferred orientation and sample prep, and may require Raman, FTIR, DSC/TGA, ssNMR, or microscopy for orthogonal specificity.
Amounts range from small milligram quantities for ID to larger amounts for validation, detection-limit studies, spiking, replicates, and retain requirements.
Raman, FTIR, DSC/TGA, DVS/KF, microscopy, ssNMR, HPLC/GC, and dissolution/residual-solids analysis complement XRPD depending on matrix and question.
FDA cares that the method is scientifically justified, specific for the intended attribute in the real matrix, controlled under the quality system, validated or verified where appropriate, data-integrity compliant, and lifecycle managed.
Common mistakes include using exploratory data as release evidence, validating the wrong matrix, ignoring sample preparation, under-documenting controls, relying on one technique when orthogonal evidence is needed, or failing to define the decision before testing.
Triclinic uses cGMP XRPD when solid-form identity, polymorph content, hydrate or solvate state, crystallinity, amorphous content, or phase purity must support release, stability, validation, or investigation decisions. Real-world applications include controlled XRPD methods for APIs and drug products, lot comparability, stability form monitoring, method transfer, specification support, and quality records that require traceable solid-state evidence.
Exploratory data can help choose a method, but release or filing-support data require controlled execution. The method must be suitable for the matrix, the quality attribute must be defined, reference standards and controls must be appropriate, and the report or CoA must say only what the data support.
| cGMP concern | Why it matters | Practical control |
|---|---|---|
| Method status | Exploratory, verified compendial, validated custom, and transferred methods have different evidence requirements. | Define status before testing and document any development, verification, validation, or transfer work. |
| Sample matrix | Specificity can fail in real drug product, excipient, talc, low-dose, or complex solid mixtures. | Use representative material, placebo/matrix controls, spike studies, or orthogonal methods where needed. |
| Data integrity | Release or stability results must survive QA review, audit, and regulatory scrutiny. | Use controlled records, system suitability, analyst review, deviations/OOS process, and traceable calculations. |
The table below lists the specific platforms, brands, models, software, detectors, and capability notes relevant to this cGMP service area.
| Instrument or platform | Brand, model, software, or detector | Additional capabilities and use |
|---|---|---|
| Powder X-ray diffraction | Rigaku SmartLab instruments; quadruple-redundant PXRD capacity; Cu source; 1D and 2D, reflection and transmission orientations | Phase identification, crystallinity, quantitative/semi-quantitative phase analysis, texture/microstructure, tablets, powders, thin films, and drug-product mapping. |
| Photon-counting 2D detection | Rigaku HyPix-3000 detector | High-count-rate, fast-readout, essentially no-noise photon-counting detection for advanced diffraction studies. |
| VT/VRH-PXRD environment | Anton Paar CHCplus Cryo and Humidity Chamber with liquid-nitrogen cooling | 2-95% RH, multiple temperature windows, vacuum/air/inert atmospheres, and program-controlled or continuous VT/VRH collection strategies. |
| cGMP and non-GMP PXRD capacity | Four powder X-ray diffractometers; three cGMP and one non-GMP system with 2D detector | Routine release/validation-ready XRPD plus advanced variable-temperature, variable-humidity, and 2D materials studies. |
This example shows why a XRPD method may need more than a single ambient pattern when the quality question involves hydrate/anhydrate risk, metastable form conversion, humidity exposure, or process excursions. Variable-temperature and variable-relative-humidity PXRD can show whether diffraction peaks change under controlled humidity and temperature conditions, which is critical when the method must support release, stability, or form-control decisions.
These examples cite Triclinic source documents, regulatory guidances, or literature relevant to this cGMP service. Download buttons are positioned at the bottom-left of each example.
Author: Triclinic Labs
Publication date: Updated 2026
Abstract: This XRPD reference explains how diffraction patterns serve as crystalline-material fingerprints and how peak positions and intensities support phase identification, form comparison, and regulated solid-form method logic.
Author: United States Pharmacopeia
Publication date: USP-NF General Chapter
Abstract: USP <941> is the compendial general chapter for X-ray powder diffraction characterization of crystalline and partially crystalline solids. It is directly relevant to cGMP XRPD method verification because it frames sample preparation, instrument control, diffraction-pattern comparison, phase identification, and quantitative or semi-quantitative use. Triclinic has verified cGMP XRPD testing for regulated solid-form, phase-identification, and release-support decisions.
Author: Triclinic Labs
Publication date: 2023
Abstract: This application note follows theophylline phase changes under controlled temperature and humidity, showing how non-ambient XRPD can support hydrate, polymorph, stability, and process-control investigations.
Author: International Council for Harmonisation / FDA
Publication date: 2024
Abstract: These harmonized guidances describe validation and development principles for analytical procedures used to assess drug-substance and drug-product quality. They anchor expectations for specificity, accuracy, precision, range, robustness, lifecycle management, and fit-for-purpose method evidence in cGMP work.
Use cGMP NMR for identity, purity, qNMR, reference-material verification, method development, validation, and release testing.
View serviceDevelop, validate, verify, and transfer wet or dry particle-size methods for release specifications and quality decisions.
View serviceUse cGMP DSC and TGA to evaluate melting, desolvation, dehydration, glass transitions, degradation, and thermal material control.
View serviceUse cGMP Raman and FTIR for raw-material ID, solid-form differentiation, mapping, contaminant ID, and validated spectroscopic methods.
View serviceUse cGMP microscopy and particle morphology evidence for identification, particle shape, foreign-material work, and regulated investigations.
View serviceUse verified or validated methods to support batch disposition, CoA issuance, stability testing, and regulatory documentation.
View serviceRun the work under cGMP when the result will support release, stability, regulatory documentation, method validation or transfer, CoA issuance, or a quality investigation rather than exploratory screening only.
Material requirements depend on method, matrix, replicate design, standards, destructive testing, retain needs, and whether method development, validation, transfer, or release testing is required. Confirm exact amounts before shipment.
Yes. The project should be scoped from the quality attribute, sample matrix, method status, and regulatory decision before selecting a technique or validation plan.
Defensible cGMP results require appropriate method status, sample traceability, reference standards, controls, system suitability, analyst training, data review, and clear reporting of limitations.
Yes. Triclinic develops, validates, and transfers cGMP XRPD methods for solid-form identification, polymorph and hydrate/solvate control, crystallinity or amorphous-content questions, quantitative phase analysis, stability monitoring, and release support. Method work can include sample preparation, scan conditions, instrument configuration, reference patterns or standards, specificity, precision, detection or quantitation limits where applicable, robustness, system suitability, and transfer to an appropriate receiving laboratory or instrument.
Instrument geometry, alignment, calibration, sample preparation, packing, particle statistics, preferred orientation, scan range, step size, counting time, data processing, reference materials, system suitability, and acceptance criteria must be controlled as applicable.
Send the sample type, intended use of the data, method or monograph if available, specification, matrix, timeline, and whether the work is exploratory, cGMP, validation, transfer, stability, release, or investigation support.
